...low-dose bromfenac, an NSAID, and is delivered via the DuraSite sustained delivery technology from Sun's InSite...

...Phase II iNSITE 1 trial in squamous non-small cell lung cancer (NSCLC) and Phase II iNSITE...

...Phase II iNSITE 1 trial in squamous non-small cell lung cancer (NSCLC) and Phase II iNSITE...

...raise $20 million. The company proposed the offering last June, when it planned to acquire InSite Vision Inc....
...when the Ranbaxy Inc. subsidiary of Sun Pharmaceutical Industries Ltd. (BSE:524715; NSE:SUNPHARMA, Mumbai, India) acquired InSite...

...Bind halted further enrollment in the open-label, international Phase II iNSITE 2 trial evaluating IV BIND-014...
...n=23). Earlier this year, Bind discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of iNSITE...

...in intent-to-treat (ITT) population of the squamous histology cohort of the open-label, international Phase II iNSITE...
...cohort but not the K-Ras ( KRAS )-mutation NSCLC cohort into the second stage of iNSITE...

...and molecularly targeted therapies. The restructuring follows data from the Phase II iNSITE 1 and iNSITE...
...iNSITE 2. In January, Bind discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of iNSITE...

...primary endpoint in the iNSITE 1 trial in non-small cell lung cancer (NSCLC), while the iNSITE...

...of about 40 patients in the squamous histology cohort of the open-label, international Phase II iNSITE...

...discontinued enrollment in the cholangiocarcinoma and bladder cancer cohorts of the open-label, international Phase II iNSITE...